Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Effects on Estrogen Receptor Mobility Underlie Antagonist Activity

DOI: 10.1158/2159-8290.CD-RW2019-118 Published September 2019
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Estrogen receptor (ER) ligands’ antagonism is dictated by their effects on intranuclear ER mobility.

  • Mechanism: Full ER antagonists immobilize ER and prevent ER-mediated increases in chromatin accessibility.

  • Impact: Screening for modulators of transcription factor mobility may be a useful avenue for drug discovery.

The estrogen receptor (ER)–targeting agent tamoxifen's active metabolite, 4-OHT, competes with estrogen (E2) for ER's ligand binding domain (LBD), accounting for its therapeutic efficacy in ER+ breast cancer. However, 4-OHT also weakly activates ER's N-terminal activation function 1 (AF1) domain, prompting a search for drugs that fully antagonize ER. Conventional wisdom is that ER degradation is a marker of strong antagonism, but Guan, Zhou, and colleagues found that ER degradation was not a reliable predictor in a study of six drugs and drug candidates. The effects of ER antagonists on the LBD did not determine their effects on cell proliferation, consistent with previous observations that the AF1 domain is also important for ER signaling. Each drug or drug candidate predicted to antagonize ER based on ER degradation altered the transcriptional profiles of cancer cell lines in distinct ways, with some activating canonical ER target genes normally induced by E2. In mice, greater transcriptional suppression of ER was associated with more powerful antitumor effects of ER antagonists. Contrary to the hypothesis that the reason the strong ER antagonists fulvestrant and GDC-0927 lack the weak ER-agonist activity of drugs like tamoxifen is that they prevent ER's binding to certain DNA sites, all E2-competitive ligands tested induced ER binding to canonical sites. Hinting at an alternative mechanism, fulvestrant and GDC-0927 binding had only a small impact on chromatin accessibility, whereas E2 and 4-OHT increased accessibility at ER binding sites. Live-cell imaging revealed that only the full antagonists fulvestrant and GDC-0927 uniquely immobilized ER by slowing intranuclear diffusion, and this immobilization dictated antagonism and ER turnover. Collectively, these results not only suggest that ER degradation capability alone should not be used as a proxy for ER antagonism, but also provide proof-of-concept that therapeutics targeting transcription-factor dynamics may be worth investigating.

Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 20191;78:949–63.e18.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 9 (9)
September 2019
Volume 9, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects on Estrogen Receptor Mobility Underlie Antagonist Activity
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effects on Estrogen Receptor Mobility Underlie Antagonist Activity
Cancer Discov September 1 2019 (9) (9) 1154; DOI: 10.1158/2159-8290.CD-RW2019-118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effects on Estrogen Receptor Mobility Underlie Antagonist Activity
Cancer Discov September 1 2019 (9) (9) 1154; DOI: 10.1158/2159-8290.CD-RW2019-118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Breast Cancer

  • Imaging Can Identify PI3Kα-Inhibitor Susceptibility in Breast Cancer
  • Prognosis-Linked FOXA1 Mutations Alter DNA Binding and Transcription
  • mSWI/SNF Component ARID1A Mediates Breast Cancer Treatment Response
Show more Breast Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement